Skip to main content
Erschienen in: Endocrine 2/2018

22.12.2017 | Original Article

Effects of growth hormone on thyroid function are mediated by type 2 iodothyronine deiodinase in humans

verfasst von: Ichiro Yamauchi, Yoriko Sakane, Takafumi Yamashita, Keisho Hirota, Yohei Ueda, Yugo Kanai, Yui Yamashita, Eri Kondo, Toshihito Fujii, Daisuke Taura, Masakatsu Sone, Akihiro Yasoda, Nobuya Inagaki

Erschienen in: Endocrine | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Growth hormone (GH) therapy in adults alters thyroid function, and acromegaly often involves thyroid disease. The present study aimed to elucidate roles and mechanisms of GH in regulating thyroid function.

Methods

We performed two retrospective observational studies, which focused on consecutive patients with severe adult GH deficiency who received recombinant human GH (rhGH) therapy (n = 20) and consecutive patients with acromegaly who underwent transsphenoidal surgery (TSS) (n = 25). In both studies, serum free triiodothyronine (fT3), free thyroxine (fT4), and fT3/fT4 ratio were examined before and after the interventions. We subsequently administered GH to four human cell lines (HepG2, TSA201, MCF7, and HTC/C3) in vitro, and examined changes in mRNA levels of iodothyronine deiodinases (D1, D2, and D3).

Results

Median serum fT3 level significantly increased after rhGH therapy from 2.38 to 2.78 pg/mL (p < 0.001), and fT4 decreased from 1.115 to 1.065 ng/dL (p = 0.081). TSS significantly decreased median serum fT3 from 3.03 to 2.53 pg/mL (p < 0.001), and increased fT4 from 1.230 to 1.370 ng/dL (p < 0.001). In vitro, GH significantly increased D2 expression at the mRNA level in HTC/C3 cells (p < 0.01), as well as D2 protein and its activity.

Conclusions

GH increased serum fT3 level and decreased serum fT4 level in humans. Our results suggest that its mechanism involves D2 upregulation. Considering this GH effect on thyroid hormone metabolism, data on thyroid function could be useful in the management of GH deficiency and acromegaly.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat A.J. Brooks, M.J. Waters, The growth hormone receptor: mechanism of activation and clinical implications. Nat. Rev. Endocrinol. 6(9), 515–525 (2010)CrossRefPubMed A.J. Brooks, M.J. Waters, The growth hormone receptor: mechanism of activation and clinical implications. Nat. Rev. Endocrinol. 6(9), 515–525 (2010)CrossRefPubMed
2.
Zurück zum Zitat A.M. Dabrowska, J.S. Tarach, M. Kurowska, A. Nowakowski, Thyroid diseases in patients with acromegaly. Arch. Med. Sci. 10(4), 837–845 (2014)CrossRefPubMed A.M. Dabrowska, J.S. Tarach, M. Kurowska, A. Nowakowski, Thyroid diseases in patients with acromegaly. Arch. Med. Sci. 10(4), 837–845 (2014)CrossRefPubMed
3.
Zurück zum Zitat S. Dagdelen, N. Cinar, T. Erbas, Increased thyroid cancer risk in acromegaly. Pituitary 17(4), 299–306 (2014)CrossRefPubMed S. Dagdelen, N. Cinar, T. Erbas, Increased thyroid cancer risk in acromegaly. Pituitary 17(4), 299–306 (2014)CrossRefPubMed
4.
Zurück zum Zitat P.H. Geelhoed-Duijvestijn, J.K. Bussemaker, F. Roelfsema, Changes in basal and stimulated TSH and other parameters of thyroid function in acromegaly after transsphenoidal surgery. Acta Endocrinol. 121(2), 207–215 (1989)PubMed P.H. Geelhoed-Duijvestijn, J.K. Bussemaker, F. Roelfsema, Changes in basal and stimulated TSH and other parameters of thyroid function in acromegaly after transsphenoidal surgery. Acta Endocrinol. 121(2), 207–215 (1989)PubMed
5.
Zurück zum Zitat P.V. Carroll, E.R. Christ, B.A. Bengtsson, L. Carlsson, J.S. Christiansen, D. Clemmons, R. Hintz, K. Ho, Z. Laron, P. Sizonenko, P.H. Sonksen, T. Tanaka, M. Thorne, Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J. Clin. Endocrinol. Metab. 83(2), 382–395 (1998)CrossRefPubMed P.V. Carroll, E.R. Christ, B.A. Bengtsson, L. Carlsson, J.S. Christiansen, D. Clemmons, R. Hintz, K. Ho, Z. Laron, P. Sizonenko, P.H. Sonksen, T. Tanaka, M. Thorne, Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J. Clin. Endocrinol. Metab. 83(2), 382–395 (1998)CrossRefPubMed
6.
Zurück zum Zitat J.O. Jorgensen, S.A. Pedersen, P. Laurberg, J. Weeke, N.E. Skakkebaek, J.S. Christiansen, Effects of growth hormone therapy on thyroid function of growth hormone-deficient adults with and without concomitant thyroxine-substituted central hypothyroidism. J. Clin. Endocrinol. Metab. 69(6), 1127–1132 (1989)CrossRefPubMed J.O. Jorgensen, S.A. Pedersen, P. Laurberg, J. Weeke, N.E. Skakkebaek, J.S. Christiansen, Effects of growth hormone therapy on thyroid function of growth hormone-deficient adults with and without concomitant thyroxine-substituted central hypothyroidism. J. Clin. Endocrinol. Metab. 69(6), 1127–1132 (1989)CrossRefPubMed
7.
Zurück zum Zitat J.O. Jorgensen, J. Moller, T. Laursen, H. Orskov, J.S. Christiansen, J. Weeke, Growth hormone administration stimulates energy expenditure and extrathyroidal conversion of thyroxine to triiodothyronine in a dose-dependent manner and suppresses circadian thyrotrophin levels: studies in GH-deficient adults. Clin. Endocrinol. 41(5), 609–614 (1994)CrossRef J.O. Jorgensen, J. Moller, T. Laursen, H. Orskov, J.S. Christiansen, J. Weeke, Growth hormone administration stimulates energy expenditure and extrathyroidal conversion of thyroxine to triiodothyronine in a dose-dependent manner and suppresses circadian thyrotrophin levels: studies in GH-deficient adults. Clin. Endocrinol. 41(5), 609–614 (1994)CrossRef
8.
Zurück zum Zitat S. Porretti, C. Giavoli, C. Ronchi, G. Lombardi, M. Zaccaria, D. Valle, M. Arosio, P. Beck-Peccoz, Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T(4) therapy become mandatory? J. Clin. Endocrinol. Metab. 87(5), 2042–2045 (2002)CrossRefPubMed S. Porretti, C. Giavoli, C. Ronchi, G. Lombardi, M. Zaccaria, D. Valle, M. Arosio, P. Beck-Peccoz, Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T(4) therapy become mandatory? J. Clin. Endocrinol. Metab. 87(5), 2042–2045 (2002)CrossRefPubMed
9.
Zurück zum Zitat N. Glynn, H. Kenny, L. Quisenberry, D.J. Halsall, P. Cook, T. Kyaw Tun, The effect of growth hormone replacement on the thyroid axis in patients with hypopituitarism: in vivo and ex vivo studies. Clin. Endocrinol. 86(5), 747–754 (2017)CrossRef N. Glynn, H. Kenny, L. Quisenberry, D.J. Halsall, P. Cook, T. Kyaw Tun, The effect of growth hormone replacement on the thyroid axis in patients with hypopituitarism: in vivo and ex vivo studies. Clin. Endocrinol. 86(5), 747–754 (2017)CrossRef
10.
Zurück zum Zitat A. Agha, D. Walker, L. Perry, W.M. Drake, S.L. Chew, P.J. Jenkins, A.B. Grossman, J.P. Monson, Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients. Clin. Endocrinol. 66(1), 72–77 (2007) A. Agha, D. Walker, L. Perry, W.M. Drake, S.L. Chew, P.J. Jenkins, A.B. Grossman, J.P. Monson, Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients. Clin. Endocrinol. 66(1), 72–77 (2007)
11.
Zurück zum Zitat M. Losa, M. Scavini, E. Gatti, A. Rossini, S. Madaschi, I. Formenti, A. Caumo, C.A. Stidley, R. Lanzi, Long-term effects of growth hormone replacement therapy on thyroid function in adults with growth hormone deficiency. Thyroid 18(12), 1249–1254 (2008)CrossRefPubMed M. Losa, M. Scavini, E. Gatti, A. Rossini, S. Madaschi, I. Formenti, A. Caumo, C.A. Stidley, R. Lanzi, Long-term effects of growth hormone replacement therapy on thyroid function in adults with growth hormone deficiency. Thyroid 18(12), 1249–1254 (2008)CrossRefPubMed
12.
Zurück zum Zitat G. Amato, G. Izzo, I. Salzano, A. Bellastella, Recombinant human growth hormone treatment at low doses does not significantly change thyroid function in growth hormone deficient adults. J. Endocrinol. Invest. 19(8), 563–566 (1996)CrossRefPubMed G. Amato, G. Izzo, I. Salzano, A. Bellastella, Recombinant human growth hormone treatment at low doses does not significantly change thyroid function in growth hormone deficient adults. J. Endocrinol. Invest. 19(8), 563–566 (1996)CrossRefPubMed
13.
Zurück zum Zitat B. Rapoport, G.D. Chazenbalk, J.C. Jaume, S.M. McLachlan, The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr. Rev. 19(6), 673–716 (1998)PubMed B. Rapoport, G.D. Chazenbalk, J.C. Jaume, S.M. McLachlan, The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr. Rev. 19(6), 673–716 (1998)PubMed
14.
Zurück zum Zitat D.L. MacLatchy, H. Kawauchi, J.G. Eales, Stimulation of hepatic thyroxine 5’-deiodinase activity in rainbow trout (Oncorhynchus mykiss) by Pacific salmon growth hormone. Comp. Biochem. Physiol. Comp. Physiol. 101(4), 689–691 (1992)CrossRefPubMed D.L. MacLatchy, H. Kawauchi, J.G. Eales, Stimulation of hepatic thyroxine 5’-deiodinase activity in rainbow trout (Oncorhynchus mykiss) by Pacific salmon growth hormone. Comp. Biochem. Physiol. Comp. Physiol. 101(4), 689–691 (1992)CrossRefPubMed
15.
Zurück zum Zitat V.M. Darras, P. Rudas, T.J. Visser, T.R. Hall, L.M. Huybrechts, A. Vanderpooten, L.R. Berghman, E. Decuypere, E.R. Kuhn, Endogenous growth hormone controls high plasma levels of 3,3’,5-triiodothyronine (T3) in growing chickens by decreasing the T3-degrading type III deiodinase activity. Domest. Anim. Endocrinol. 10(1), 55–65 (1993)CrossRefPubMed V.M. Darras, P. Rudas, T.J. Visser, T.R. Hall, L.M. Huybrechts, A. Vanderpooten, L.R. Berghman, E. Decuypere, E.R. Kuhn, Endogenous growth hormone controls high plasma levels of 3,3’,5-triiodothyronine (T3) in growing chickens by decreasing the T3-degrading type III deiodinase activity. Domest. Anim. Endocrinol. 10(1), 55–65 (1993)CrossRefPubMed
16.
Zurück zum Zitat D. Salvatore, H. Tu, J.W. Harney, P.R. Larsen, Type 2 iodothyronine deiodinase is highly expressed in human thyroid. J. Clin. Invest. 98(4), 962–968 (1996)CrossRefPubMedPubMedCentral D. Salvatore, H. Tu, J.W. Harney, P.R. Larsen, Type 2 iodothyronine deiodinase is highly expressed in human thyroid. J. Clin. Invest. 98(4), 962–968 (1996)CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat B. Gereben, D. Salvatore, J.W. Harney, H.M. Tu, P.R. Larsen, The human, but not rat, dio2 gene is stimulated by thyroid transcription factor-1 (TTF-1). Mol. Endocrinol. 15(1), 112–124 (2001)CrossRefPubMed B. Gereben, D. Salvatore, J.W. Harney, H.M. Tu, P.R. Larsen, The human, but not rat, dio2 gene is stimulated by thyroid transcription factor-1 (TTF-1). Mol. Endocrinol. 15(1), 112–124 (2001)CrossRefPubMed
18.
Zurück zum Zitat K. Chihara, A. Shimatsu, N. Hizuka, T. Tanaka, Y. Seino, Y. Katofor, A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur. J. Endocrinol. 157(1), 19–27 (2007)CrossRefPubMed K. Chihara, A. Shimatsu, N. Hizuka, T. Tanaka, Y. Seino, Y. Katofor, A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur. J. Endocrinol. 157(1), 19–27 (2007)CrossRefPubMed
19.
Zurück zum Zitat K. Kageyama, T. Nigawara, S. Sakihara, S. Takayasu, K. Terui, T. Moriyama, T. Suda, Diagnostic usefulness of the growth hormone-releasing peptide-2 test as a substitute for the insulin tolerance test in hypopituitarism. Endocr. J. 55(4), 777–783 (2008)CrossRefPubMed K. Kageyama, T. Nigawara, S. Sakihara, S. Takayasu, K. Terui, T. Moriyama, T. Suda, Diagnostic usefulness of the growth hormone-releasing peptide-2 test as a substitute for the insulin tolerance test in hypopituitarism. Endocr. J. 55(4), 777–783 (2008)CrossRefPubMed
20.
Zurück zum Zitat L. Katznelson, E.R. Laws Jr., S. Melmed, M.E. Molitch, M.H. Murad, A. Utz, J.A. Wass, Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933–3951 (2014)CrossRefPubMed L. Katznelson, E.R. Laws Jr., S. Melmed, M.E. Molitch, M.H. Murad, A. Utz, J.A. Wass, Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933–3951 (2014)CrossRefPubMed
21.
Zurück zum Zitat T. Isojima, A. Shimatsu, S. Yokoya, K. Chihara, T. Tanaka, N. Hizuka, A. Teramoto, K.I. Tatsumi, K. Tachibana, N. Katsumata, R. Horikawa, Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. Endocr. J. 59(9), 771–780 (2012)CrossRefPubMed T. Isojima, A. Shimatsu, S. Yokoya, K. Chihara, T. Tanaka, N. Hizuka, A. Teramoto, K.I. Tatsumi, K. Tachibana, N. Katsumata, R. Horikawa, Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. Endocr. J. 59(9), 771–780 (2012)CrossRefPubMed
22.
Zurück zum Zitat T. Enomoto, H. Sugawa, D. Inoue, M. Miyamoto, S. Kosugi, T. Takahashi, N. Kitamura, I. Yamamoto, J. Konishi, T. Mori et al.. Establishment of a human undifferentiated thyroid cancer cell line producing several growth factors and cytokines. Cancer 65(9), 1971–1979 (1990)CrossRefPubMed T. Enomoto, H. Sugawa, D. Inoue, M. Miyamoto, S. Kosugi, T. Takahashi, N. Kitamura, I. Yamamoto, J. Konishi, T. Mori et al.. Establishment of a human undifferentiated thyroid cancer cell line producing several growth factors and cytokines. Cancer 65(9), 1971–1979 (1990)CrossRefPubMed
23.
Zurück zum Zitat Y. Kanou, A. Hishinuma, K. Tsunekawa, K. Seki, Y. Mizuno, H. Fujisawa, T. Imai, Y. Miura, T. Nagasaka, C. Yamada, T. Ieiri, M. Murakami, Y. Murata, Thyroglobulin gene mutations producing defective intracellular transport of thyroglobulin are associated with increased thyroidal type 2 iodothyronine deiodinase activity. J. Clin. Endocrinol. Metab. 92(4), 1451–1457 (2007)CrossRefPubMed Y. Kanou, A. Hishinuma, K. Tsunekawa, K. Seki, Y. Mizuno, H. Fujisawa, T. Imai, Y. Miura, T. Nagasaka, C. Yamada, T. Ieiri, M. Murakami, Y. Murata, Thyroglobulin gene mutations producing defective intracellular transport of thyroglobulin are associated with increased thyroidal type 2 iodothyronine deiodinase activity. J. Clin. Endocrinol. Metab. 92(4), 1451–1457 (2007)CrossRefPubMed
24.
Zurück zum Zitat T.L. Fonseca, M. Correa-Medina, M.P. Campos, G. Wittmann, J.P. Werneck-de-Castro, R. Arrojo e Drigo, M. Mora-Garzon, C.B. Ueta, A. Caicedo, C. Fekete, B. Gereben, R.M. Lechan, A.C. Bianco, Coordination of hypothalamic and pituitary T3 production regulates TSH expression. J. Clin. Invest. 123(4), 1492–1500 (2013)CrossRefPubMedPubMedCentral T.L. Fonseca, M. Correa-Medina, M.P. Campos, G. Wittmann, J.P. Werneck-de-Castro, R. Arrojo e Drigo, M. Mora-Garzon, C.B. Ueta, A. Caicedo, C. Fekete, B. Gereben, R.M. Lechan, A.C. Bianco, Coordination of hypothalamic and pituitary T3 production regulates TSH expression. J. Clin. Invest. 123(4), 1492–1500 (2013)CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat P. Burman, A.G. Johansson, A. Siegbahn, B. Vessby, F.A. Karlsson, Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J. Clin. Endocrinol. Metab. 82(2), 550–555 (1997)PubMed P. Burman, A.G. Johansson, A. Siegbahn, B. Vessby, F.A. Karlsson, Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J. Clin. Endocrinol. Metab. 82(2), 550–555 (1997)PubMed
26.
Zurück zum Zitat W.M. Drake, D. Coyte, C. Camacho-Hubner, N.M. Jivanji, G. Kaltsas, D.F. Wood, P.J. Trainer, A.B. Grossman, G.M. Besser, J.P. Monson, Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J. Clin. Endocrinol. Metab. 83(11), 3913–3919 (1998)CrossRefPubMed W.M. Drake, D. Coyte, C. Camacho-Hubner, N.M. Jivanji, G. Kaltsas, D.F. Wood, P.J. Trainer, A.B. Grossman, G.M. Besser, J.P. Monson, Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J. Clin. Endocrinol. Metab. 83(11), 3913–3919 (1998)CrossRefPubMed
27.
Zurück zum Zitat J.P. Span, G.F. Pieters, C.G. Sweep, A.R. Hermus, A.G. Smals, Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement. J. Clin. Endocrinol. Metab. 85(3), 1121–1125 (2000)CrossRefPubMed J.P. Span, G.F. Pieters, C.G. Sweep, A.R. Hermus, A.G. Smals, Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement. J. Clin. Endocrinol. Metab. 85(3), 1121–1125 (2000)CrossRefPubMed
28.
Zurück zum Zitat A.C. Bianco, G. Anderson, D. Forrest, V.A. Galton, B. Gereben, B.W. Kim, P.A. Kopp, X.H. Liao, M.J. Obregon, R.P. Peeters, S. Refetoff, D.S. Sharlin, W.S. Simonides, R.E. Weiss, G.R. Williams, American Thyroid Association Guide to investigating thyroid hormone economy and action in rodent and cell models. Thyroid 24(1), 88–168 (2014)CrossRefPubMedPubMedCentral A.C. Bianco, G. Anderson, D. Forrest, V.A. Galton, B. Gereben, B.W. Kim, P.A. Kopp, X.H. Liao, M.J. Obregon, R.P. Peeters, S. Refetoff, D.S. Sharlin, W.S. Simonides, R.E. Weiss, G.R. Williams, American Thyroid Association Guide to investigating thyroid hormone economy and action in rodent and cell models. Thyroid 24(1), 88–168 (2014)CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat D.J. Chia, P. Rotwein, Defining the epigenetic actions of growth hormone: acute chromatin changes accompany GH-activated gene transcription. Mol. Endocrinol. 24(10), 2038–2049 (2010)CrossRefPubMedPubMedCentral D.J. Chia, P. Rotwein, Defining the epigenetic actions of growth hormone: acute chromatin changes accompany GH-activated gene transcription. Mol. Endocrinol. 24(10), 2038–2049 (2010)CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat A.L. Maia, B.W. Kim, S.A. Huang, J.W. Harney, P.R. Larsen, Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J. Clin. Invest. 115(9), 2524–2533 (2005)CrossRefPubMedPubMedCentral A.L. Maia, B.W. Kim, S.A. Huang, J.W. Harney, P.R. Larsen, Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J. Clin. Invest. 115(9), 2524–2533 (2005)CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat H.J. Schneider, M. Buchfelder, H. Wallaschofski, A. Luger, G. Johannsson, P.H. Kann, A. Mattsson, Proposal of a clinical response score and predictors of clinical response to 2 years of GH replacement therapy in adult GH deficiency. Eur. J. Endocrinol. 173(6), 843–851 (2015)CrossRefPubMed H.J. Schneider, M. Buchfelder, H. Wallaschofski, A. Luger, G. Johannsson, P.H. Kann, A. Mattsson, Proposal of a clinical response score and predictors of clinical response to 2 years of GH replacement therapy in adult GH deficiency. Eur. J. Endocrinol. 173(6), 843–851 (2015)CrossRefPubMed
32.
Zurück zum Zitat U. Feldt-Rasmussen, G. Brabant, D. Maiter, B. Jonsson, A. Toogood, M. Koltowska-Haggstrom, A.K. Rasmussen, M. Buchfelder, B. Saller, B.M. Biller, Response to GH treatment in adult GH deficiency is predicted by gender, age, and IGF1 SDS but not by stimulated GH-peak. Eur. J. Endocrinol. 168(5), 733–743 (2013)CrossRefPubMed U. Feldt-Rasmussen, G. Brabant, D. Maiter, B. Jonsson, A. Toogood, M. Koltowska-Haggstrom, A.K. Rasmussen, M. Buchfelder, B. Saller, B.M. Biller, Response to GH treatment in adult GH deficiency is predicted by gender, age, and IGF1 SDS but not by stimulated GH-peak. Eur. J. Endocrinol. 168(5), 733–743 (2013)CrossRefPubMed
33.
Zurück zum Zitat E.J. Barbosa, J. Koranyi, H. Filipsson, B.A. Bengtsson, C.L. Boguszewski, G. Johannsson, Models to predict changes in serum IGF1 and body composition in response to GH replacement therapy in GH-deficient adults. Eur. J. Endocrinol. 162(5), 869–878 (2010)CrossRefPubMed E.J. Barbosa, J. Koranyi, H. Filipsson, B.A. Bengtsson, C.L. Boguszewski, G. Johannsson, Models to predict changes in serum IGF1 and body composition in response to GH replacement therapy in GH-deficient adults. Eur. J. Endocrinol. 162(5), 869–878 (2010)CrossRefPubMed
34.
Zurück zum Zitat J. Svensson, N. Finer, P. Bouloux, J. Bevan, B. Jonsson, A.F. Mattsson, M. Lundberg, P.E. Harris, M. Koltowska-Haggstrom, J.P. Monson, Growth hormone (GH) replacement therapy in GH deficient adults: predictors of one-year metabolic and clinical response. Growth Horm. IGF Res. 17(1), 67–76 (2007)CrossRefPubMed J. Svensson, N. Finer, P. Bouloux, J. Bevan, B. Jonsson, A.F. Mattsson, M. Lundberg, P.E. Harris, M. Koltowska-Haggstrom, J.P. Monson, Growth hormone (GH) replacement therapy in GH deficient adults: predictors of one-year metabolic and clinical response. Growth Horm. IGF Res. 17(1), 67–76 (2007)CrossRefPubMed
35.
Zurück zum Zitat E. Cacciari, P. Tassoni, A. Cicognani, P. Pirazzoli, S. Salardi, A. Balsamo, A. Cassio, S. Zucchini, C. Colli, D. Tassinari et al.. Value and limits of pharmacological and physiological tests to diagnose growth hormone (GH) deficiency and predict therapy response: first and second retesting during replacement therapy of patients defined as GH deficient. J. Clin. Endocrinol. Metab. 79(6), 1663–1669 (1994)PubMed E. Cacciari, P. Tassoni, A. Cicognani, P. Pirazzoli, S. Salardi, A. Balsamo, A. Cassio, S. Zucchini, C. Colli, D. Tassinari et al.. Value and limits of pharmacological and physiological tests to diagnose growth hormone (GH) deficiency and predict therapy response: first and second retesting during replacement therapy of patients defined as GH deficient. J. Clin. Endocrinol. Metab. 79(6), 1663–1669 (1994)PubMed
36.
Zurück zum Zitat K. Iwaku, J.Y. Noh, A. Minagawa, Y. Kosuga, M. Suzuki, K. Sekiya, M. Matsumoto, H. Ohye, Y. Kunii, A. Yoshihara, N. Watanabe, K. Mukasa, K. Ito, K. Ito, Determination of pediatric reference levels of FT3, FT4 and TSH measured with ECLusys kits. Endocr. J. 60(6), 799–804 (2013)CrossRefPubMed K. Iwaku, J.Y. Noh, A. Minagawa, Y. Kosuga, M. Suzuki, K. Sekiya, M. Matsumoto, H. Ohye, Y. Kunii, A. Yoshihara, N. Watanabe, K. Mukasa, K. Ito, K. Ito, Determination of pediatric reference levels of FT3, FT4 and TSH measured with ECLusys kits. Endocr. J. 60(6), 799–804 (2013)CrossRefPubMed
Metadaten
Titel
Effects of growth hormone on thyroid function are mediated by type 2 iodothyronine deiodinase in humans
verfasst von
Ichiro Yamauchi
Yoriko Sakane
Takafumi Yamashita
Keisho Hirota
Yohei Ueda
Yugo Kanai
Yui Yamashita
Eri Kondo
Toshihito Fujii
Daisuke Taura
Masakatsu Sone
Akihiro Yasoda
Nobuya Inagaki
Publikationsdatum
22.12.2017
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2018
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1495-y

Weitere Artikel der Ausgabe 2/2018

Endocrine 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.